Therapeutic and Prophylactic Cancer Vaccines
Authors:
- Pamela L. BeattyPBPamela L. Beatty
- Olivera J. FinnOFOlivera J. Finn
- 1 January 2016
- book chapter
- Published by Elsevier
- p. 542-549
Abstract
No abstract availableThis publication has 87 references indexed in Scilit:
- Ligand Binding and Signaling of Dendritic Cell Immunoreceptor (DCIR) Is Modulated by the Glycosylation of the Carbohydrate Recognition DomainPLOS ONE, 2013
- Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomasAnnals of the New York Academy of Sciences, 2013
- Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigenOncoImmunology, 2012
- Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor developmentJournal of Experimental Medicine, 2007
- Preliminary Analysis of Patients With Progressive Renal Cell Carcinoma Vaccinated With CA9-peptide–Pulsed Mature Dendritic CellsJournal of Immunotherapy, 2007
- Dendritic cells and the control of immunityNature, 1998
- MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas.Journal of Clinical Pathology, 1997
- Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.Journal of Clinical Oncology, 1990
- Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.Proceedings of the National Academy of Sciences, 1989